Elizabeth Jaffee

Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived.

Cytokine gene-modified cell-based cancer vaccines.

Focus on pancreas cancer.

Pancreatic cancer.

To live or not to live: that depends on GAGE?

Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo.

Cytokine modified tumor vaccines.

Genetically engineered tumor cell vaccine in a head and neck cancer model.

Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays.

Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.

Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy.

Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells.

Spatial distribution of tumor vaccine improves efficacy.

HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.

Cancer vaccines: an old idea comes of age.

Toward a breast cancer vaccine: work in progress.

A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin.

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice.

Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.

Augmenting the potency of breast cancer vaccines: combined modality immunotherapy.

Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens.

Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.

Immunotherapy for pancreatic cancer - science driving clinical progress.

Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms.

Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy.

Cancer vaccines in combination with multimodality therapy.

Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology.

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Ductal access for prevention and therapy of mammary tumors.

Mechanisms of immune evasion by tumors.

Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion.

Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model.

Cancer immunologists and cancer biologists: why we didn't talk then but need to now.

A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.

Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.

Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting.

Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer.

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.

Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus setting.

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.

Use of tumour-responsive T cells as cancer treatment.

Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.

Genetic mutations associated with cigarette smoking in pancreatic cancer.

OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.

SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.

Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.

Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma.

Cellular vaccine approaches.

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.

Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.

Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.

Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer.

Increased expression of DNA repair genes in invasive human pancreatic cancer cells.

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Defining the critical hurdles in cancer immunotherapy.

Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.

The determinants of tumour immunogenicity.

Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenografts.

Whole cell vaccines--past progress and future strategies.

Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy.

Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.

Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs).

Effects of genomic changes in hepatitis B virus on postoperative recurrence and survival in patients with hepatocellular carcinoma.

Targeting the right regulatory T-cell population for tumor immunotherapy.

Vaccines for pancreatic cancer.

Personalized chemotherapy profiling using cancer cell lines from selectable mice.

Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.

Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation.

Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma.

Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance.

Women in oncology: progress, challenges, and keys to success.

Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances.

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine.

Harnessing immune responses in the tumor microenvironment: all signals needed.

Peptidases released by necrotic cells control CD8+ T cell cross-priming.

Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design.

Tumor immunology: multidisciplinary science driving basic and clinical advances.

Vaccine therapy for pancreatic cancer.

Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice.

Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?

Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia.

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.

Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.

A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte-Macrophage Colony Stimulating Factor-Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer.

Immunobiology of radiotherapy: new paradigms.

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.

A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer.